DNA-encoded Library Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service (Kits & Reagents, Encoded Libraries, Design & Synthesis Services, Screening Services, Others), By Therapeutic Area (Oncology, Infectious Diseases, Cardiovascular Diseases, Neurological Diseases, Autoimmune Diseases, Metabolic Diseases, Others), By Application (Hit Generation / Identification, Hit to Lead, Hit Validation / Optimization, Others), By End Use (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Others), By Region and Competition, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 785.46 Million
CAGR (2026-2031)	14.12%
Fastest Growing Segment	Hit Validation / Optimization
Largest Market	North America
Market Size (2031)	USD 1734.98 Million

Market Overview

The Global DNA-encoded Library Market is projected to grow from USD 785.46 Million in 2025 to USD 1734.98 Million by 2031 at a 14.12% CAGR. A DNA-encoded library (DEL) represents a highly efficient drug discovery platform, comprising vast collections of chemical compounds synthesized with unique DNA tags for identification. The primary drivers supporting the market's expansion include the increasing demand for expedited and cost-effective early-stage drug discovery methods, the growing investment in pharmaceutical research and development, and the necessity for high-throughput screening solutions capable of exploring extensive chemical spaces. These factors underpin the adoption of DEL technology across pharmaceutical and biotechnology sectors.

However, market expansion could be impeded by the inherent complexity involved in library design and synthesis, necessitating specialized expertise and advanced infrastructure. Despite these challenges, the utility of DELs in accelerating lead identification remains significant. According to the American Chemical Society (ACS), a presentation in August 2025 highlighted that GSK's DNA-encoded libraries contained over 1 trillion unique small molecules.

Key Market Drivers

The increasing demand for efficient drug discovery platforms significantly propels the global DNA-encoded library market by addressing the critical need for accelerated and cost-effective identification of novel drug candidates. Traditional drug discovery methods are often time-consuming and resource-intensive, whereas DEL technology offers a streamlined approach to explore vast chemical spaces. This efficiency allows for rapid screening of billions of compounds against biological targets. For instance, according to Amgen, in April 2025, the company highlighted in "Driving Drug Design Using DNA Encoded Libraries" that its DEL technology enables screening 2 billion molecules in one morning, a process that would traditionally take approximately 50 years. This capability directly translates into reduced timelines and lower operational costs during early-stage drug development.

Concurrently, rising investments and strategic collaborations in pharmaceutical research and development are vital in expanding the adoption and capabilities of DNA-encoded libraries. These financial commitments and partnerships enable the development of more extensive and diverse DELs, alongside advanced screening methodologies. Companies are increasingly pooling resources and expertise to leverage these platforms for complex target identification. According to Charles River Laboratories International, Inc., in October 2025, in "Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities," their collaboration provides access to X-Chem’s DEL platform featuring over 15 billion compounds. Further reflecting the market's expanding reach, according to HitGen Inc., in April 2026, the company has built collaboration partnerships with several hundred biopharmaceutical research organizations worldwide using its DEL technology. Such initiatives are accelerating the pipeline for small molecule drug discovery.

Download Free Sample Report

Key Market Challenges

The inherent complexity associated with DNA-encoded library design and synthesis represents a significant impediment to the expansion of the Global DNA-encoded Library Market. Developing and managing these vast chemical collections requires highly specialized expertise in synthetic chemistry, molecular biology, and bioinformatics. Furthermore, the establishment and maintenance of the advanced infrastructure necessary for high-throughput screening, DNA sequencing, and data analysis incur substantial capital and operational expenditures. This specialized requirement limits the number of organizations capable of effectively implementing DNA-encoded library technology, particularly smaller biotechnology firms or academic institutions with constrained resources.

The substantial investment in both human capital and technological infrastructure acts as a formidable barrier to entry and wider adoption, directly slowing overall market growth by restricting the pool of potential users and innovators. The necessity for these high-level resources prolongs development timelines and increases the overall cost burden, consequently diminishing the appeal and accessibility of DNA-encoded library platforms for broader application in drug discovery. According to the European Federation of Pharmaceutical Industries and Associations, in 2024, the pharmaceutical industry collectively invested approximately €55 billion in research and development in Europe, reflecting the significant financial commitment required for advanced discovery platforms. This substantial capital outflow for research and development underscores the resource intensity that complex technologies like DNA-encoded libraries contribute to, thereby challenging their widespread adoption in a competitive and cost-sensitive environment.

Key Market Trends

The integration of Artificial Intelligence and Machine Learning (AI/ML) into DNA-encoded library platforms represents a significant trend, enhancing the efficiency and effectiveness of drug discovery beyond traditional screening throughput. These advanced computational methods are increasingly employed for rational library design, predicting compound properties, and streamlining the analysis of vast datasets generated during DEL screening. By leveraging AI/ML, researchers can more accurately identify potential hit compounds, optimize their characteristics, and accelerate the lead identification process. According to NVIDIA, in February 2026, in its "Survey Reveals AI Is Delivering Clear Return on Investment in Healthcare" report, 46% of pharmaceutical and biotechnology respondents identified AI for drug discovery and development as a top return on investment use case.

Another pivotal trend is the increased focus on "undruggable" and challenging targets, where DNA-encoded libraries offer a unique advantage due to their capacity to explore vast chemical spaces. Many disease-relevant proteins historically lacked suitable binding pockets for conventional small molecule drugs. DEL technology, with its ability to screen billions of diverse compounds, provides an avenue to discover novel chemical matter for these complex targets, opening new therapeutic possibilities. This trend reflects a strategic pivot by pharmaceutical companies. For instance, according to Stat News, in January 2026, Parabilis Therapeutics secured $305 million in funding specifically for pursuing traditionally "undruggable" targets, highlighting the substantial investment in this area.

Segmental Insights

The Hit Validation / Optimization segment is experiencing the most rapid growth within the Global DNA-encoded Library Market, primarily due to the essential need to refine initial drug candidates. This expansion is driven by the imperative to enhance crucial pharmacological properties such as potency, selectivity, solubility, and metabolic stability of compounds identified through DNA-encoded library screening. While DNA-encoded libraries excel in identifying potential hits, these often require extensive optimization to address inherent challenges, including physicochemical characteristics influenced by the DNA tag. The increasing demand from pharmaceutical and biotechnology companies for more time-efficient and cost-effective drug discovery processes further accelerates this segment, as advancements in DNA-encoded library technology are increasingly applied to systematically optimize compounds.

Regional Insights

North America holds a leading position in the Global DNA-encoded Library Market, primarily due to its well-established pharmaceutical and biotechnology ecosystem. The region benefits from substantial research and development expenditure and a robust research infrastructure that fosters innovation. The presence of numerous key market players and a culture of strong collaborations between academic institutions and pharmaceutical companies further accelerate the adoption and advancement of DNA-encoded library platforms. Additionally, favorable regulatory support and significant funding from agencies such as the National Institutes of Health (NIH) and the recognition of DNA-encoded libraries as valid screening tools by the Food and Drug Administration (FDA) bolster the region's prominent position in drug discovery.

Recent Developments

• In October 2025, Charles River Laboratories International, Inc. announced a strategic collaboration with X-Chem, a leader in DNA-encoded library (DEL) technology. This partnership was established to enhance Charles River's hit identification capabilities, providing its clients with access to X-Chem's proprietary DEL platform, which contains over 15 billion compounds. The collaboration integrates Charles River's expertise in protein production and assay development with X-Chem's robust DEL screening to create a seamless workflow from hit identification to lead optimization. This initiative aims to accelerate the discovery of novel therapeutics and offers a scalable solution for biopharmaceutical organizations in the global DNA-encoded library market.
• In August 2025, Cube Biotech and X-Chem announced the successful conclusion of Project DEL-MP, a collaborative initiative demonstrating the suitability of copolymer-stabilized membrane proteins for DNA-encoded library (DEL) screening. This partnership combined Cube Biotech's NativeMP™ technology, which stabilizes functional membrane proteins in near-native conformations, with X-Chem's DEL platform. The collaboration opens new avenues for drug discovery against challenging membrane protein targets, previously considered difficult to screen effectively. This development is a significant breakthrough in applying DEL technology, expanding its impact and fostering innovation across numerous therapeutic areas within the global DNA-encoded library market.
• In July 2025, Orogen Therapeutics, Chemspace, and Enamine formed a strategic collaboration focused on developing unique REAL-driven DNA-encoded small molecule libraries. This partnership integrates Orogen's artificial intelligence-enabled DNA-encoded library (DEL) technology with Chemspace's extensive chemical datasets and Enamine's REAL design principles. The objective is to advance next-generation drug discovery by combining powerful computational capabilities with vast chemical diversity. This collaboration aims to identify novel chemical matter against challenging drug targets, thereby enhancing the efficiency and scope of drug development within the global DNA-encoded library market.
• In April 2025, Amgen unveiled advancements in its DNA-encoded library (DEL) platform, showcasing its capacity to significantly accelerate drug discovery. This internal research breakthrough enables scientists to efficiently screen billions of chemical compounds, identifying promising small molecules for next-generation therapies in various disease areas. The technology uses DNA barcodes to link chemical compounds, allowing for rapid, high-throughput screening that would traditionally take decades. Amgen's DEL platform facilitates the discovery of molecules with enhanced specificity, including those that can act as "glues" to modulate protein interactions, thereby expanding the potential for new therapeutic interventions in the global DNA-encoded library market.

Key Market Players

• X-Chem, Inc.
• Nuevolution A/S
• HitGen Inc.
• Pharmaron Beijing Co., Ltd.
• WuXi AppTec Co., Ltd.
• Novartis AG
• GlaxoSmithKline plc
• Pfizer Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company

By Product & Service	By Therapeutic Area	By Application	By End Use	By Region
Kits & Reagents Encoded Libraries Design & Synthesis Services Screening Services Others	Oncology Infectious Diseases Cardiovascular Diseases Neurological Diseases Autoimmune Diseases Metabolic Diseases Others	Hit Generation / Identification Hit to Lead Hit Validation / Optimization Others	Academic & Research Institutes Pharmaceutical & Biotechnology Companies Contract Research Organizations Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global DNA-encoded Library Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• DNA-encoded Library Market, By Product & Service:

• Kits & Reagents
• Encoded Libraries
• Design & Synthesis Services
• Screening Services
• Others

• DNA-encoded Library Market, By Therapeutic Area:

• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Diseases
• Autoimmune Diseases
• Metabolic Diseases
• Others

• DNA-encoded Library Market, By Application:

• Hit Generation / Identification
• Hit to Lead
• Hit Validation / Optimization
• Others

• DNA-encoded Library Market, By End Use:

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Others

• DNA-encoded Library Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE